Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study

NCT05974839 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.

NCT NCT05974839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05974839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study
Lead sponsor
State University of New York at Buffalo
Phase
Observational
Overall status
Completed
Start date
October 1, 2023
Completion date
February 28, 2024
Enrollment
732 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis